




HIV PrEP Eligibility and Monitoring

What Are the Options?

Risk Group	Men Who Have Sex With Men	Transgender Women	Heterosexual Men	Heterosexual Women	Transgender Men
 Daily Oral FTC/TDF 200 mg/300 mg	FDA approved, guideline recommended				
 Daily Oral FTC/TAF 200 mg/25 mg	FDA approved, guideline recommended			Off label, not recommended (studies underway)	Off label, not recommended (unless risk from anal sex only)
 Injectable LA CAB	FDA approved, guideline recommended			FDA approved, CDC recommended (except in pregnancy)	

Clinical Monitoring at Initiation and During PrEP

Assessment	Daily Oral FTC/TDF	Daily Oral FTC/TAF	Injectable LA CAB
HIV Ab/Ag and HIV RNA testing*	✓ Every 3 months	✓ Every 3 months	✓ Every 2 months
STI testing	✓	✓	✓
Hepatitis B serology	✓	✓	
Hepatitis C serology	✓	✓ People who inject drugs, transgender women, men who have sex with men	
Renal function	✓ Every 12 months if age <50 years and eCrCl ≥90 mL/min at PrEP initiation Every 6 months if age ≥50 years or eCrCl <90 mL/min at PrEP initiation	✓	
Lipids		✓ Every 12 months	
Counsel on adherence, risk reduction	✓	✓	✓
Assess interest in continuing PrEP	✓	✓	✓

*Complete HIV testing at initiation of PrEP and during every follow up visit.

practicingclinicians.com/hiv-prevention-resource-center/resource-center.php

CDC PrEP Guidelines. December 2021.